SuperworthCellectar Biosciences CLRB
- Market cap
- $11.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Cellectar Biosciences' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $7M+31% | $7.7M+42% | $7.1M+12% | $7.3M+20% | $5.5M−22% | $6.2M−20% | $3.4M−52% | $2.4M−68% | $2.5M−54% | $3.2M−49% | $3M−12% | $4.6M+91% |
| SG&A | $2.4M−2% | $4.8M+144% | $4.9M+109% | $6.4M+195% | $7.8M+229% | $6.5M+36% | $3M−40% | $3.6M−43% | $2.3M−70% | $2.5M−61% | $2.8M−6% | $2.6M−28% |
| −$9.4M+20% | −$12.5M+69% | −$12M+38% | −$13.7M+65% | −$13.3M+42% | −$12.7M+2% | −$6.4M−47% | −$6M−56% | −$4.9M−64% | −$5.7M−55% | −$5.8M−10% | −$7.2M+19% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$17.5M+124% | −$7.9M−37% | −$26.6M+271% | −$919.4K−91% | −$14.7M−16% | −$2.4M−70% | −$6.6M−75% | −$5.4M+493% | −$4.4M−70% | −$5.3M+125% | −$5.7M−14% | −$6.9M+27% |
| −$46.50+21% | −$15.60−59% | −$27.30+42% | −$5.43−80% | −$12.13−74% | −$1.69−89% | −$4.30−84% | −$3.39−38% | −$1.41−88% | −$1.29−24% | −$1.33−69% | −$0.57−83% | |
| 377K+85% | 500.8K+52% | 978.2K+161% | 1.2M+233% | 1.3M+252% | 1.4M+179% | 1.5M+57% | 1.6M+29% | 3.2M+138% | 4.1M+193% | 4.2M+176% | 12.2M+660% |
EPS, diluted: 15 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY15: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Cellectar Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CLRBCellectar Biosciences | $11.5M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Cellectar Biosciences
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .